THE health sector in Australia needs to focus on data to ensure everything it does is measurable, with a transition from "volume-based" to "value-based" care inevitable, according to Chris Hourigan, president of Janssen Japan and former Medicines Australia board member.
Speaking yesterday at the Mumbrella Health Marketing Summit in Sydney, Hourigan urged delegates to focus on areas which are in need of disruption - hospitals, healthcare IT and primary care - all of which suffer from disparate stakeholders, payment pathways and obsolete technology.
Volume-based health systems - where payments are made regardless of outcome - are not sustainable in the long term as global populations age and chronic disease prevalence increases.
"Now is the time to evolve," he said, to a new paradigm where remuneration is based on the value added by health professionals and the outcomes achieved.
He said providers need to focus on "how we can leverage data to prove our value and enhance our credibility, trust and reputation," with modern technology enabling post-marketing collection of information on how products are being used and what the effective outcomes are.
Hourigan said as a highly innovative country, Australia has plenty of opportunity to improve the system, but industry fragmentation means "there is no ten or 15-year vision for how we can improve health outcomes".
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Aug 18
